share_log

Fresenius Medical Care AG & Co. KGaA (ETR:FME) Given a €57.95 Price Target at Berenberg Bank

Defense World ·  Aug 9, 2022 04:31

Berenberg Bank set a €57.95 ($59.13) price target on Fresenius Medical Care AG & Co. KGaA (ETR:FME – Get Rating) in a report issued on Monday, Borsen Zeitung reports.

Other research analysts have also issued research reports about the company. Deutsche Bank Aktiengesellschaft set a €37.00 ($37.76) price objective on Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 2nd. Warburg Research set a €42.00 ($42.86) price objective on Fresenius Medical Care AG & Co. KGaA in a report on Friday. Barclays set a €40.00 ($40.82) price objective on Fresenius Medical Care AG & Co. KGaA in a report on Friday. Jefferies Financial Group set a €64.00 ($65.31) price objective on Fresenius Medical Care AG & Co. KGaA in a report on Monday, July 25th. Finally, JPMorgan Chase & Co. set a €23.00 ($23.47) price objective on Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 29th.

Get Fresenius Medical Care AG & Co. KGaA alerts:

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of FME stock opened at €36.79 ($37.54) on Monday. The company has a market capitalization of $10.79 billion and a P/E ratio of 13.18. The business's 50 day moving average is €46.85 and its two-hundred day moving average is €54.81. The company has a current ratio of 1.18, a quick ratio of 0.70 and a debt-to-equity ratio of 88.41. Fresenius Medical Care AG & Co. KGaA has a 12-month low of €35.08 ($35.80) and a 12-month high of €69.96 ($71.39).

Fresenius Medical Care AG & Co. KGaA Company Profile

(Get Rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

See Also

  • Home Depot, Lowe's On Track To Grow 2022 Earnings
  • Could Smaller be Better for Investors in Norwegian Cruise Lines?
  • Walmart Or Target: Which Is The Stronger Stock?
  • Volume Surges Spark Turnarounds for These 3 Stocks
  • Can Etsy Continue to Thrive After the Pandemic?

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment